… Sodzi Sodzi-Tettey, has defended the Institute’s GH¢13 million expenditure on training, workshops and conferences in 2025, insisting the activities are critical to its mandate and capital-intensive. …
… Chief Executive Officer of the National Vaccine Institute (NVI), Dr Sodzi Sodzi-Tettey, disclosed this to journalists in Parliament, saying the project was progressing through a partnership involving local scientific institutions, private manufacturers and an Indonesian pharmaceu …
Chief Executive Officer of the National Vaccine Institute (NVI), Dr Sodzi Sodzi-Tettey, has disclosed that Ghana is preparing to pre-qualify Ghanaian companies to manufacture vaccines for the local and wider African market. …
… Chief Executive of the National Vaccine Institute, Dr Sodzi Sodzi-Tettey, said Ghana has the scientific expertise and an increasingly capable pharmaceutical industry needed to develop health products tailored to local needs. …
… Sodzi Sodzi-Tettey, the institute is working towards producing its first locally manufactured vaccine by 2027 and achieving full local vaccine production by 2030. …
… Sodzi Sodzi-Tettey, the institute is working towards producing its first locally manufactured vaccine by 2027 and achieving full local vaccine production by 2030. …
The National Vaccine Institute's CEO has defended the Institute's GH¢13 million expenditure on training, workshops and conferences in 2025, arguing the spending supports development of Ghana's vaccine manufacturing sector by building capacity among researchers, manufacturers and regulators. The defence comes after the Auditor-General reported the Institute moved from a GH¢36 million profit to a GH¢21 million loss within the financial year.
The National Vaccine Institute's CEO has defended the Institute's GH¢13 million expenditure on training, workshops and conferences in 2025, arguing the spending supports development of Ghana's vaccine manufacturing sector by building capacity among researchers, manufacturers and regulators. The defence comes after the Auditor-General reported the Institute moved from a GH¢36 million profit to a GH¢21 million loss within the financial year.
Ghana is expected to produce its first locally manufactured vaccine—a tetanus-diphtheria vaccine—by 2027 through Atlantic Lifesciences Limited, with production supported by a partnership involving local institutions, private manufacturers, and an Indonesian pharmaceutical company. The National Vaccine Institute has completed a technology transfer agreement with Indonesia to reduce Ghana's reliance on imported vaccines.
The CEO of Ghana's National Vaccine Institute said the country is preparing to pre-qualify Ghanaian companies to manufacture vaccines for local and wider African markets, following Ghana's decision to join the Africa Pool Procurement Mechanism. A regional meeting is planned for November in Accra to launch an application process for assessing and pre-qualifying eligible companies.
Ghana has signed a Memorandum of Understanding on August 21, 2026, to participate in the African Pooled Procurement Mechanism, giving Ghanaian pharmaceutical and vaccine manufacturers access to a larger continental market and creating more predictable demand for locally manufactured health products.
Ghana has signed a Memorandum of Understanding with the Africa Centres for Disease Control and Prevention to join the African Pooled Procurement Mechanism, granting Ghanaian vaccine and pharmaceutical manufacturers access to a market of about 1.4 billion people across all 55 African Union member states.
Ghana has been selected as one of eight countries worldwide to pilot a WHO benchmarking tool designed to assess and strengthen institutional capacity for conducting high-quality clinical trials. The tool examines seven functional areas across 32 objectives and 112 outcomes, and 13 Ghanaian institutions participated in an assessment exercise.
Eight Ghanaian research institutions and pharmaceutical companies have been awarded €2 million in grants under the PharmaVax Ghana programme to develop vaccines, medicines, and health products. The projects, jointly funded by Germany and the EU and implemented by GIZ, cover innovations in malaria treatment, monoclonal antibodies, diagnostics, and herbal remedies for various conditions.
Ghana's National Vaccine Institute has been admitted to the WHO-managed Global Clinical Trials Forum, a network that supports stronger clinical trial systems globally. The membership provides Ghana with technical support and collaboration opportunities at no financial cost.
Ghana's National Vaccine Institute has been admitted to the WHO-managed Global Clinical Trials Forum, a network supporting the development of stronger clinical trial systems globally. The membership provides Ghana with technical support and collaboration opportunities at no financial cost to the institute.
Ghana's National Vaccine Institute is seeking partnerships with investors including Ghana Exim Bank, Afreximbank, and the International Finance Corporation to fund local vaccine manufacturers, as GAVI funding ends in 2030 and Ghana will need to fund vaccines locally at about $50 million in four years. The NVI has signed a tech transfer agreement with PT Biopharma of Indonesia for tetanus-diphtheria vaccine manufacturing locally by 2027.
A nationwide survey by the National Vaccine Institute found that only 14.3 per cent of Ghanaians are aware of plans to begin local vaccine production in 2027, highlighting the need for intensified public education despite high general confidence in vaccines. The survey of 13,905 valid responses across all 16 regions and 55 districts revealed regional disparities, with rural communities in northern Ghana showing stronger vaccine acceptance than urbanised regions like Greater Accra and Ashanti.
A government official recounts his first year working under President John Mahama, highlighting the President's grasp of public sector processes and the swift implementation of solutions, and noting that Mahama's Accra Reset Agenda has gained attention in the global health community.